Clinical trials: Stage II Rectal Cancer
CRC, Colorectal Cancer
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
This is a multicenter, open-label, dose-escalation/dose-expansion, Phase Ib/II study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of HDM2017 combination therapy in participants…
- Trial name
- NCT07805551
- Testing
- HDM2017, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Rectal Cancer
An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer
The purpose of this study is to determine whether an optimal dose of [6R] 5,10-methylenetetrahydrofolate (arfolitixorin) in combination with pemetrexed are effective in pre-operative treatment of patients with resectable rectal…
- Trial name
- NCT01397305
- Testing
- [6R] 5,10-methylenetetrahydrofolate (arfolitixorin), Pemetrexed
- Where
- Sweden
- Volunteers
- 24 people
- Sponsor
- Isofol Medical AB
Metastatic Colorectal Cancer
Phase II Efficacy Study of AZD6244 in Colorectal Cancer
The purpose of the study is to assess if there is benefit when using AZD6244 in the treatment if metastatic colorectal cancer in comparison with another treatment called capecitabine.
- Trial name
- NCT00514761
- Testing
- AZD6244, Capecitabine
- Where
- 3 sites in Brazil
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Mid-low Locally Advanced Rectal Cancer
rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer
This is a multi-center, randomized, phase II study, aimed to evaluate the efficacy of investigational product at a dose of 1800 µg/day when given in combination with TNT.
- Trial name
- rSIFN-co (NCT07662278)
- Testing
- Recombinant Super-Compound Interferon (rSIFN-co), Total Neo-adjuvant therapy
- Volunteers
- 90 people
- Sponsor
- Sichuan Huiyang Life Science and Technology Corporation
Colorectal Neoplasms
Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer
Study to evaluate the anti-tumour activity, safety and pharmacokinetics of unlabelled sibrotuzumab administered weekly (seven days +/- one day) at a dose of 100 mg (a total of 12 administrations) in patients with metastatic…
- Trial name
- NCT02198274
- Testing
- BIBH 1
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma
Oral Rigosertib for Squamous Cell Carcinoma
The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT01807546
- Testing
- rigosertib
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Traws Pharma, Inc.
Metastatic Colorectal Cancer
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired…
- Trial name
- NCT02083653
- Testing
- Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC)
- Where
- 54 sites in United States, Austria and 8 more
- Volunteers
- 254 people
- Sponsor
- Symphogen A/S
Colorectal Cancer
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
This is an open label, multicenter Phase Ib/II clinical study on the efficacy and safety of AK119 and AK112 in combination with or without chemotherapy, and AK112 monotherapy in pMMR/MSS CRC
- Trial name
- NCT05846867
- Testing
- AK119, AK112, Oxaliplatin
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Akeso
Colorectal Cancer
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy…
- Trial name
- APOLLON (NCT02613221)
- Testing
- Panitumumab + TAS-102
- Where
- 32 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Colorectal Cancer
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic…
- Trial name
- NCT03555149
- Testing
- Regorafenib, Atezolizumab, Imprime PGG
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
This study will assess the safety and anticancer activity of TQB2922 injection given under the skin together with chemotherapy in adults with colorectal cancer that has spread, cannot be removed by surgery, and has no RAS or BRAF…
- Trial name
- NCT07844187
- Testing
- TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium)
- Where
- 16 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Colorectal Cancer
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)
This will be a randomized, open-label, multicenter, Phase II study with primary objectives to assess whether expression of select chemotherapy markers is associated with progression-free survival (PFS) in participants treated…
- Trial name
- MAVERICC (NCT01374425)
- Testing
- 5-Fluorouracil, Bevacizumab, Irinotecan
- Where
- 79 sites in United States, Canada and 5 more
- Volunteers
- 376 people
- Sponsor
- Genentech, Inc.
Advanced Colorectal Cancer, Colorectal Cancer
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with…
- Trial name
- NCT00498407
- Testing
- CP-4055
- Where
- 4 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Clavis Pharma
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche